Open AccessA case report of intraventricular and intrathecal tigecycline infusions for an extensively drug-resistant intracranial Acinetobacter baumannii infection
Author(s) -
Ziwei Deng,
Wang Jin,
Caian Qiu,
Yi Yang,
Zhihua Shi,
Jian-liang Zhou
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000015139
Subject(s) - tigecycline , medicine , acinetobacter baumannii , intrathecal , drug resistance , cerebrospinal fluid , intensive care medicine , anesthesia , antibiotics , microbiology and biotechnology , genetics , bacteria , pseudomonas aeruginosa , biology
Rationale: The treatment of intracranial Acinetobacter baumannii infections is made difficult by multidrug-resistance poor drug penetration through the blood-brain barrier (BBB). Although tigecycline appears to be effective against A baumannii , it is only administered intravenously because it does not readily cross the BBB. The addition of intraventricular (IVT) or intrathecal infusions of tigecycline could revolutionize clinical therapy for intracranial A baumannii infections. However, there are few reports on the successful use of such treatments. Patient concerns: We report the case of a 17-year-old male who presented with high fever and neck rigidity after intracranial drainage. Diagnosis: Intracranial infection with extensively drug-resistant A baumannii after intracranial drainage. Interventions: On the advice of a clinical pharmacist, the patient was administered intrathecal infusions of tigecycline after treatment failure with IVT tigecycline. Outcomes: The patient's body temperature returned to normal. Thereafter, the patient was in good clinical condition without signs of cerebrospinal fluid infection and tuberculosis. Lessons: However, when central nervous system infections fail IVT tigecycline, clinicians should consider changing to intrathecal tigecycline infusions rather than raising the dose of IVT tigecycline. In addition, the co-administration of tigecycline with other drugs that can penetrate the BBB should not be ruled out.